Switch to:
Also traded in: Germany, Israel, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MZOR's Cash-to-Debt is ranked higher than
86% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. MZOR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MZOR' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.61  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.77
MZOR's Equity-to-Asset is ranked higher than
73% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MZOR: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
MZOR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.79 Max: 0.92
Current: 0.77
0.6
0.92
Interest Coverage No Debt
MZOR's Interest Coverage is ranked higher than
89% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. MZOR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MZOR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 40.16
Beneish M-Score: -1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -39.81
MZOR's Operating Margin % is ranked lower than
72% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. MZOR: -39.81 )
Ranked among companies with meaningful Operating Margin % only.
MZOR' s Operating Margin % Range Over the Past 10 Years
Min: -994.62  Med: -69.35 Max: -34.58
Current: -39.81
-994.62
-34.58
Net Margin % -37.66
MZOR's Net Margin % is ranked lower than
71% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. MZOR: -37.66 )
Ranked among companies with meaningful Net Margin % only.
MZOR' s Net Margin % Range Over the Past 10 Years
Min: -938.71  Med: -102.73 Max: -37.66
Current: -37.66
-938.71
-37.66
ROE % -30.08
MZOR's ROE % is ranked lower than
69% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. MZOR: -30.08 )
Ranked among companies with meaningful ROE % only.
MZOR' s ROE % Range Over the Past 10 Years
Min: -54.35  Med: -40.75 Max: -25.81
Current: -30.08
-54.35
-25.81
ROA % -24.08
MZOR's ROA % is ranked lower than
68% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. MZOR: -24.08 )
Ranked among companies with meaningful ROA % only.
MZOR' s ROA % Range Over the Past 10 Years
Min: -44.52  Med: -30.88 Max: -23.21
Current: -24.08
-44.52
-23.21
ROC (Joel Greenblatt) % -573.28
MZOR's ROC (Joel Greenblatt) % is ranked lower than
83% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. MZOR: -573.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MZOR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3532.44  Med: -964.44 Max: -573.28
Current: -573.28
-3532.44
-573.28
3-Year Revenue Growth Rate 13.20
MZOR's 3-Year Revenue Growth Rate is ranked higher than
74% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. MZOR: 13.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MZOR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 6.8  Med: 31.9 Max: 90
Current: 13.2
6.8
90
3-Year EBITDA Growth Rate 31.90
MZOR's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MZOR: 31.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MZOR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 1.15 Max: 31.9
Current: 31.9
-10.1
31.9
3-Year EPS without NRI Growth Rate -9.70
MZOR's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MZOR: -9.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MZOR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 0.1 Max: 25.3
Current: -9.7
-9.7
25.3
GuruFocus has detected 5 Warning Signs with Mazor Robotics Ltd MZOR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MZOR's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MZOR Guru Trades in Q2 2016

George Soros Sold Out
Jim Simons 44,800 sh (-44.21%)
» More
Q3 2016

MZOR Guru Trades in Q3 2016

Jim Simons Sold Out
» More
Q1 2017

MZOR Guru Trades in Q1 2017

Steven Cohen 23,800 sh (New)
» More
Q2 2017

MZOR Guru Trades in Q2 2017

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MZOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3842
Compare:TSE:7817, SHSE:603579, TSE:6960, NAS:BABY, SZSE:300273, SHSE:600587, SZSE:000607, XPAR:GBT, SZSE:300298, SZSE:300216, SHSE:603387, HKSE:00853, SZSE:300238, XBRU:IBAB, NAS:MDXG, OTCPK:NMRD, HKSE:01302, TSE:4548, NAS:CSII, NAS:KTWO » details
Traded in other countries:M0SA.Germany, MZOR.Israel, MZRTF.USA,
Headquarter Location:Israel
Mazor Robotics Ltd is engaged in the development, production and marketing of medical devices for supporting surgical procedures in the field of orthopedics and neurosurgery.

Mazor Robotics is a medical devices company. The company has one business segment, Surgical & Medical Equipment, that is engaged in the development, production, and marketing of medical devices primarily oriented toward helping with guided surgery and computer assisted surgery. Mazor Robotics offers various products including the Mazor X surgical guidance system and Renaissance surgical guidance system. The Renaissance system aids with spinal surgery. The company generates the vast majority of revenue in Israel.

Top Ranked Articles about Mazor Robotics Ltd

Investors: Are you buying stock in AK Steel Holding Corp., Alibaba, Mazor Robotics Ltd, NVIDIA or Philip Morris International?
Thinking about buying stock in Disney, Johnson & Johnson, Eli Lilly, Mazor Robotics Ltd or Wells Fargo?
DEADLINE TODAY: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Mazor Robotics Ltd. and Reminds Investors with Losses to Contact the Firm
DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Mazor Robotics Ltd. and Reminds Investors with Losses to Contact the Firm
DEADLINE ALERT:  Brower Piven Reminds Investors Of Upcoming Deadline And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Mazor Robotics Ltd. (NASDAQ: MZOR) To Contact The Firm
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Mazor Robotics Ltd. - MZOR
MZOR Investors Deadline Reminder: Hagens Berman Reminds Investors in Mazor Robotics Ltd. of the August 8, 2017 Lead Plaintiff Deadline in the Pending Securities Class Action
Rosen Law Firm Reminds Mazor Robotics Ltd. Investors of Important Deadline in Class Action - MZOR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mazor Robotics Ltd. of Class Action Lawsuit and Upcoming Deadline - MZOR
Investor Alert: Kaplan Fox Announces Investigation Of Mazor Robotics Ltd.

Ratios

vs
industry
vs
history
PB Ratio 20.25
MZOR's PB Ratio is ranked lower than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MZOR: 20.25 )
Ranked among companies with meaningful PB Ratio only.
MZOR' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 5.81 Max: 22.21
Current: 20.25
1.22
22.21
PS Ratio 25.64
MZOR's PS Ratio is ranked lower than
90% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MZOR: 25.64 )
Ranked among companies with meaningful PS Ratio only.
MZOR' s PS Ratio Range Over the Past 10 Years
Min: 2.61  Med: 12.82 Max: 48.42
Current: 25.64
2.61
48.42
EV-to-EBIT -61.89
MZOR's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. MZOR: -61.89 )
Ranked among companies with meaningful EV-to-EBIT only.
MZOR' s EV-to-EBIT Range Over the Past 10 Years
Min: -85.4  Med: -15.8 Max: -0.4
Current: -61.89
-85.4
-0.4
EV-to-EBITDA -66.19
MZOR's EV-to-EBITDA is ranked lower than
99.99% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. MZOR: -66.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
MZOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.7  Med: -16.7 Max: -0.4
Current: -66.19
-93.7
-0.4
EV-to-Revenue 24.67
MZOR's EV-to-Revenue is ranked lower than
87% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. MZOR: 24.67 )
Ranked among companies with meaningful EV-to-Revenue only.
MZOR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6  Med: 10.9 Max: 48.3
Current: 24.67
0.6
48.3
Current Ratio 3.92
MZOR's Current Ratio is ranked higher than
71% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. MZOR: 3.92 )
Ranked among companies with meaningful Current Ratio only.
MZOR' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 5.97 Max: 22.44
Current: 3.92
2.59
22.44
Quick Ratio 3.51
MZOR's Quick Ratio is ranked higher than
74% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MZOR: 3.51 )
Ranked among companies with meaningful Quick Ratio only.
MZOR' s Quick Ratio Range Over the Past 10 Years
Min: 2.41  Med: 5.6 Max: 22.17
Current: 3.51
2.41
22.17
Days Inventory 118.25
MZOR's Days Inventory is ranked higher than
59% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. MZOR: 118.25 )
Ranked among companies with meaningful Days Inventory only.
MZOR' s Days Inventory Range Over the Past 10 Years
Min: 103.17  Med: 172.72 Max: 274.41
Current: 118.25
103.17
274.41
Days Sales Outstanding 47.06
MZOR's Days Sales Outstanding is ranked higher than
83% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. MZOR: 47.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
MZOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.39  Med: 76.24 Max: 99.83
Current: 47.06
34.39
99.83
Days Payable 58.95
MZOR's Days Payable is ranked higher than
50% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. MZOR: 58.95 )
Ranked among companies with meaningful Days Payable only.
MZOR' s Days Payable Range Over the Past 10 Years
Min: 58.95  Med: 171.8 Max: 395.39
Current: 58.95
58.95
395.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
MZOR's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. MZOR: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MZOR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.4  Med: -20 Max: -5.3
Current: -5.3
-27.4
-5.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 35.87
MZOR's Price-to-Net-Cash is ranked lower than
73% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.17 vs. MZOR: 35.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MZOR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.63  Med: 7.12 Max: 39.33
Current: 35.87
1.63
39.33
Price-to-Net-Current-Asset-Value 24.57
MZOR's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. MZOR: 24.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MZOR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.33  Med: 6.08 Max: 26.94
Current: 24.57
1.33
26.94
Price-to-Tangible-Book 20.94
MZOR's Price-to-Tangible-Book is ranked lower than
89% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. MZOR: 20.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MZOR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.3  Med: 5.64 Max: 22.96
Current: 20.94
1.3
22.96
Price-to-Median-PS-Value 2.00
MZOR's Price-to-Median-PS-Value is ranked lower than
83% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. MZOR: 2.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MZOR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.98 Max: 3.61
Current: 2
0.2
3.61
Earnings Yield (Greenblatt) % -1.63
MZOR's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. MZOR: -1.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MZOR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -250.5  Med: -6.3 Max: -1.2
Current: -1.63
-250.5
-1.2

More Statistics

Revenue (TTM) (Mil) $48.85
EPS (TTM) $ -0.78
Beta1.76
Short Percentage of Float0.00%
52-Week Range $20.19 - 59.59
Shares Outstanding (Mil)25.59 (ADR)

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 52 73
EPS ($) -0.45 -0.32
EPS without NRI ($) -0.45 -0.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
30.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}